AstraZeneca to sell commercial rights to Atacand in more than 70 countries to Cheplapharm
The FINANCIAL -- AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil ...
